文献速递肾癌与肾肿瘤

临床T1a肾肿瘤主动监测与初始干预比较:12年前瞻性研究

Active Surveillance vs Primary Intervention for Clinical T1a Kidney Tumors: 12-Year Experience of the Delayed Intervention and Surveillance for Small Renal Masses Prospective Comparative Study.
PubMed 文献 · J Urol · 2025-04-22

该多机构前瞻性比较研究纳入958例小肾占位患者(581例主动监测,377例初始干预),中位随访4.15年。

要点

  • 主动监测的肿瘤特异性生存不劣于初始干预,4年及以后累积发生率仅0.19%。
  • 初始干预组总生存更高,但差异可能由竞争性死亡风险解释。
  • 581例主动监测中88例转为延迟干预,进展定义(含生长速率)需重新审视。

核心结论

  • 在小肾占位疑似肾细胞癌患者中,主动监测的肿瘤特异性生存不劣于初始干预。
  • 主动监测与初始干预的总生存差异最可能归因于主动监测组竞争性死亡风险增加。
  • 进展的事先定义(包括生长速率)应重新考虑。

研究设计与样本

  • 多机构前瞻性比较研究,2009年至2022年纳入临床T1a小肾占位患者。
  • 共958例患者入组,581例选择主动监测,377例选择初始干预。
  • 主动监测组中88例最终转为延迟干预。
  • 登记队列中存活患者的中位随访时间为4.15年(IQR 2.11-7.31),406例随访≥5年。

主要发现

  • 竞争风险肿瘤特异性生存累积发生率函数显示,主动监测4年及以后为0.19%(95%CI 0.3%-1.4%),初始干预为0.68%(95%CI 0.17%-2.7%)。
  • Kaplan-Meier分析显示初始干预组总生存高于主动监测组:4年95% vs 88%,6年92% vs 81%,8年90% vs 66%,10年85% vs 64%。

临床怎么用

  • 对于临床T1a小肾占位疑似肾细胞癌患者,主动监测可作为初始干预的替代选择,肿瘤特异性生存不劣于初始干预。
  • 向患者解释总生存差异可能源于竞争性死亡风险,而非肿瘤进展。
  • 进展定义(包括生长速率)应重新考虑,避免过度干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Active surveillance (AS) is an alternative to primary intervention (PI) in the management of small renal masses (SRMs; clinical stage T1a). However, AS remains underutilized due to a lack of strong, prospective data. We herein report mature outcomes after a 12-year experience with the Delayed Intervention and Surveillance for Small Renal Masses Registry. MATERIALS AND METHODS: This was a multi-institutional prospective comparative study from 2009 to 2022 of patients with SRM who chose to undergo AS or PI. Primary outcomes were cancer-specific survival (CSS) and overall survival (OS). RESULTS: A total of 958 patients were enrolled; 581 chose AS, and 377 chose PI. Ultimately, 88 of 581 AS patients crossed over to delayed intervention. The median follow-up time for the registry was 4.15 years (IQR: 2.11-7.31) among patients who were still alive, with 406 patients followed for ≥ 5 years. Competing-risk CSS cumulative incidence function accounting for other causes of mortality for AS at 4 years and beyond is 0.19% (95% CI: 0.3%-1.4%), and for PI at 4 years and beyond is 0.68% (95% CI: 0.17%-2.7%). Gray's test for statistical differences between CSS CI curves of PI vs AS showed no statistical difference (P = .4). However, Kaplan-Meier analysis of OS showed it to be higher in patients undergoing PI compared with AS at 4 years (95% vs 88%), 6 years (92% vs 81%), 8 years (90% vs 66%), and 10 years (85% vs 64%); this difference was statistically significant; log-rank P < .001. CONCLUSIONS: In our study cohort, AS is not inferior to PI in patients with SRM suspicious for renal cell carcinoma. The difference in OS between AS and PI is most likely attributable to the increased risk of death from competing causes among AS patients. A priori definitions of progression, including growth rate, should be reconsidered.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Alkhatib KY, Cheaib JG, Pallauf M, et al. Active Surveillance vs Primary Intervention for Clinical T1a Kidney Tumors: 12-Year Experience of the Delayed Intervention and Surveillance for Small Renal Masses Prospective Comparative Study. J Urol. 2025. PMID: 40262276. doi:10.1097/JU.0000000000004583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。